Anti-cancer Drug Raw Powder Dasatinib CAS: 302962-49-8 High Purity Pharmaceutica

Informations de base:

Nom du produit: Dasatinib
Synonymes: Dasatinib(BMS-354825);BMS-354825;N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-pipérazinyle]-2-methyl-4-pyrimidinyl]aminé]-5-thiazolecarboxamide;5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-pipérazinyle]-2-methyl-4-pyrimidinyl]aminé]-;Dasatinib;N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]aminé]-1,3-thiazole-5-carboxamide;N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide;2-{6-[4-(2-HYDROXY-ETHYL)-PIPERAZIN-1-YL]-2-METHYL-PYRIMIDIN-4-YLAMINO}-THIAZOLE-5-CARBOXYLIC ACID (2-CHLORO-6-METHYL-PHENYL)-AMIDE
CAS: 302962-49-8
MF: C22H28ClN7O3S
MW: 488.01
EINECS: 1806241-263-5
Point de fusion: 275-286°C
Température de stockage: -20°C Congélateur
Apparence: White solid

Usage:

Leukemia drug Dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in May 2009, the US Food and Drug Administration (FDA) formally approved the sale of dasatinib , It has been clinically used for the treatment of various chronic myeloid leukemia (CML), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) and the treatment of patients with solid tumors.

October 28, 2010 ,the FDA approved dasatinib (Sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed Philadelphia chromosome-positive called chronic myeloid leukemia (Ph + CP-CML) . The disease is a blood and bone marrow disease associated with genetic abnormality .

An open-label randomized clinical trial conducted in patients with CP-CML evaluated the safety and efficacy of dasatinib . Common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, mal de tête, musculoskeletal pain, and rash.

October 11, 2011, the US Food and Drug Administration (FDA) said the leukemia drug dasatinib (Sprycel, Bristol-Myers Squibb Company) might increase pulmonary arterial hypertension (PAH) risk. Pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . PAH symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms from other similar symptoms.

Depuis 2006 Dasatinib was approved in the US market ,there had been 12 associated pulmonary hypertension events ,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib.

Notre service

1.100% La politique de réexpédition est notre base commerciale. 100% de réexpédition immédiatement si votre colis reste en douane pendant 4 jours et n'est pas mis à jour.
2.Remboursement total pour 15 jours d'insatisfaction avec la qualité.
3.Nous pouvons fournir des échantillons gratuits.
4.Nous avons un emballage spécial ,Il peut être facilement passé à la douane. Il sera plus sûr.
5.Notre société coopère à long terme avec DHL.EMS.Fedex et ainsi de suite. Il peut être envoyé à votre main plus rapidement. La photo du colis doit être offerte dans les 12 heures suivant la réception de votre paiement de stéroïdes.
6.Si vous avez la chance de venir en Chine. Je peux te montrer notre labo.
7.Notre société a WU, MG, TT, et les moyens de paiement Bitcoin à l'avance. Vous pouvez payer 95% pour les peptides coûtent au début pour la commande, le reste peut nous offrir dans votre prochaine commande;